Table 2. Objective response rate, disease control rate, TTP and survival analysis in NSCLC patients treated with gefitinib whose tumours showed no or low gain in copy numbers for the HER3 gene (HER3 FISH−) and high levels of gain for HER3 gene copy number (HER3 FISH+).
|
HER3 FISH status
|
||||
|---|---|---|---|---|
| Outcome | Total Pts N=82 No. (%) | Positive N=22 No. (%) | Negative N=60 No. (%) | P-value |
| Total | 82 (100) | 22 (26.8) | 60 (73.2) | |
| Objective Response rate (OR) | 11 (13.4) | 4 (18.2) | 7 (11.7) | 0.47 |
| Disease control rate (DCR=OR +stable disease) | 31 (37.8) | 10 (45.5) | 21 (35.0) | 0.38 |
| Progressive Disease | 51 (62.6) | 12 (54.5) | 39 (65.0) | |
| Time to progression (months) | 2.9 | 3.7 | 2.7 | 0.044* |
| Median survival (months) | 11 | 10.1 | 11.3 | 0.75 |
*
Statistically significant.